|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Grant income | |||||
| Total revenue and grant income | |||||
| Operating Expenses | |||||
| Direct costs | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Operating Loss | |||||
| Nonoperating Income and Expense | |||||
| Interest income | |||||
| Change in fair value of warrant liabilities | |||||
| Interest expense | |||||
| Other expense | |||||
| Total nonoperating income and expense | |||||
| Pretax Loss | |||||
| Income (loss) before income tax expense (benefit) | |||||
| Income tax expense (benefit) | |||||
| Net Income (Loss) | |||||
| Share of net loss (income) of equity method investee | |||||
| Net Loss Attributable to Common Stockholders | |||||
| Other Comprehensive Income | |||||
| Comprehensive Loss Attributable to Common Stockholders | |||||
| Basic loss per share | |||||
| Diluted loss per share | |||||
| Weighted average shares outstanding - Basic | |||||
| Weighted average shares outstanding - Diluted | |||||
Loading...